Almac Discovery is a biopharmaceutical company focussed on the discovery and development of novel therapeutics for oncology indications. e.g. ALM201 is a potent yet non-toxic targetted tubulin binding peptide inhibitor of angiogenesis.
One in three of us will get cancer and increases in life expectancy indices will exacerbate this statistic in the future. Most current chemotherapeutics have devastating side effects including hair loss, nausea, weakened immunity and fatigue to name but a few.Specialties
BioMoti exists to transform the treatment of cancer patients by doing things differently. BioMoti seeks to transform the treatment of cancer by targeted delivery of therapeutics to the intracellular space of cancer cells; aiming to dramatically increase efficacy whilst reducing side effects.
Oncojans™ are a new class of therapeutic microparticles that target and gain entry to the interior of cancer cells where they slowly release drugs at the point of need whilst sparing healthy tissue. The Oncojan™ platform is compatible with a range of drug classes from small molecule therapeutics to larger biologicals.
MOTI1001 is BioMoti’s lead Oncojan™ based ovarian cancer candidate that has shown very promising potential in early preclinical studies.
Targeted delivery of therapeutics to the interior of cancer cells
BioPartner UK, BIA, One Nucleus
The UK BioIndustry Association and One Nucleus are your UK points of contact at Biotech Showcase 2014, representing BioPartner and supporting the UK group.
BioPartner is an independent, accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. Through the BioPartnership Programme, BioPartner assists companies to attend major international biopharma conferences by providing access to government grants and heavily discounted entry fees.
Clinical Network Services (UK)
Clinical Network Services (CNS) offers a full and integrated drug development consultancy to small – medium sized Biotech companies from inception through to end of phase II clinical trial programs. CNS offers a unique service that brings together BioDesk; an intelligent product development and regulatory planning service, with our highly experienced regional clinical operations and data management teams.
Crescendo has developed a unique transgenic mouse which generates fully human VH single domain antibody fragments in the absence of contaminating murine light chains.
VH are the smallest, most robust antibody fragments with advantages for engineering of bispecific and multivalent products, tissue and tumour penetration, topical delivery and simple manufacture.
Crescendo is applying the platform to a pipeline focused on inflammation and oncology, and topical delivery.